OverviewChartProfileKey statisticsFinancialsNewsTraderScreen

SWEDISH ORPHAN BIOVIT.SK1/  SE0000872095  /

Berlin
15/10/2024  08:08:20 Chg. - Volume Bid08:02:04 Ask08:02:04 Market Capitalization Dividend Y. P/E Ratio
26.000EUR - 0
Turnover: 0.000		 25.860Bid Size: 50 26.100Ask Size: 50 9.27 bill.EUR - -
GlobeNewswire 24/05 Sobi to present new myelofibrosis data at the ASCO 2024 Annual Meeting
GlobeNewswire 24/05 Sobi Receives US FDA Fast Track Designation for Emapalumab-lzsg being investigated in Macrophage Act...
GlobeNewswire 07/09/2021 Nature Medicine publishes positive phase 3 anakinra study results in patients with COVID-19 pneumoni...
GlobeNewswire 22/12/2020 FDA Approves KINERET® (anakinra) for the Treatment of Deficiency of IL-1 Receptor Antagonist (DIRA)
GlobeNewswire 04/05/2016 Swedish Orphan Biovitrum AB (publ): Bo Jesper Hansen sells 8 million shares
GlobeNewswire 29/04/2016 Sobi signs manufacturing agreements with Pfizer
GlobeNewswire 27/04/2016 Sobi publishes its report for the first quarter 2016
GlobeNewswire 27/04/2016 Sobi publishes 2015 Annual Report
GlobeNewswire 26/04/2016 Orfadin® Oral Suspension approved in the US
GlobeNewswire 22/04/2016 Sobi signs licensing agreement with Affibody for IL-1
GlobeNewswire 21/04/2016 European patent granted on new formulation of Kineret® (anakinra)
GlobeNewswire 20/04/2016 Notice of annual general meeting in Swedish Orphan Biovitrum AB (publ)
GlobeNewswire 11/04/2016 COMP recommends that Alprolix® maintains orphan designation for treatment of haemophilia B
GlobeNewswire 24/03/2016 European Commission approves transfer of marketing authorisation for Elocta® to Sobi
GlobeNewswire 08/03/2016 Sobi announces new date for Annual General Meeting of shareholders
GlobeNewswire 29/02/2016 Sobi updates outlook for 2016
GlobeNewswire 26/02/2016 Sobi and Biogen receive positive opinion from CHMP for Alprolix® (rFIXFc) for the treatment of haemo...
GlobeNewswire 26/02/2016 Bo Jesper Hansen to step down as Chairman of Sobi - Håkan Björklund to be nominated as new Chairman ...
GlobeNewswire 26/02/2016 Sobi publishes its report for the fourth quarter and full year 2015
GlobeNewswire 23/02/2016 Sobi to initiate clinical development programs in acute gout and Still's disease, and receives US pa...
GlobeNewswire 17/02/2016 Invitation - Presentation of Sobi's fourth quarter and full year results 2015
GlobeNewswire 28/01/2016 Sobi to present new interim ASPIRE data at EAHAD congress suggesting that patients can reduce bleedi...
GlobeNewswire 19/01/2016 Sobi's Orfadin® oral suspension granted European patent
GlobeNewswire 14/01/2016 Chief Medical Officer Birgitte Volck to leave Sobi
GlobeNewswire 11/01/2016 Sobi(TM) announces commercial launch of Elocta® in first countries in Europe